Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study by Antonio Llombart-Cussac, Antonio Anton-Torres, Beatriz Rojas, Raquel Andrés, Noelia Martinez, César A. Rodríguez, Sara Marin, Teresa Puértolas, Alejandro Falcón González, María Leonor Fernández-Murga, Carlos Hagen, Manuel Ruiz-Borrego

Get full text

Patient Perspective on the Management of Cancer Pain in Spain by Jesús García-Foncillas MD, PhD, Antonio Antón-Torres MD, Fernando Caballero-Martínez MD, PhD, Francisco J Campos BS, Margarita Feyjoo MD, Alfonso Gómez de Liaño MD, Diana Monge MD, MPH, PhD, Carlos Camps MD, PhD

Get full text

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial by Javier Salvador Bofill, Fernando Moreno Anton, Cesar Augusto Rodriguez Sanchez, Elena Galve Calvo, Cristina Hernando Melia, Eva Maria Ciruelos Gil, Maria Vidal, Begoña Jiménez-Rodriguez, Luis De la Cruz Merino, Noelia Martínez Jañez, Rafael Villanueva Vazquez, Ruben de Toro Salas, Antonio Anton Torres, Isabel Manuela Alvarez Lopez, Joaquin Gavila Gregori, Vanesa Quiroga Garcia, Elena Vicente Rubio, Juan De la Haba-Rodriguez, Santiago Gonzalez-Santiago, Nieves Diaz Fernandez, Agusti Barnadas Molins, Blanca Cantos Sanchez de Ibargüen, Juan Ignacio Delgado Mingorance, Meritxell Bellet Ezquerra, Sonia de Casa, Asuncion Gimeno, Miguel Martin

Get full text